Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials-Reference-Cited by-同舟云学术

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Published:2020-09-11 Issue:22 Volume:126 Page:4867-4877
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Borghaei Hossein¹^ORCID,Langer Corey J.²,Paz‐Ares Luis³,Rodríguez‐Abreu Delvys⁴,Halmos Balazs⁵,Garassino Marina C.⁶,Houghton Baerin⁷,Kurata Takayasu⁸,Cheng Ying⁹,Lin Jianxin¹⁰,Pietanza M. Catherine¹⁰,Piperdi Bilal¹⁰,Gadgeel Shirish M.¹¹

Affiliation:

1. Hematology and OncologyFox Chase Cancer Center Philadelphia Pennsylvania

2. Department of Medicine Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania

3. Department of Medical Oncology Hospital Universitario 12 de Octubre, Universidad Complutense and CIBERONC Madrid Spain

4. Complejo Hospitalario Universitario Insular Materno‐Infantil de Gran CanariaUniversidad de Las Palmas de Gran Canaria Las Palmas de Gran Canaria Spain

5. Montefiore Einstein Center for Cancer Care New York New York

6. Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

7. Mid North Coast Cancer Institute, Port Macquarie Base Hospital Port Macquarie New South Wales Australia

8. Department of Thoracic Oncology Kansai Medical University Hospital Osaka Japan

9. Jilin Cancer Hospital Changchun China

10. Merck & Co, Inc Kenilworth New Jersey

11. Rogel Cancer Center University of Michigan Ann Arbor Michigan

Funder

Merck Sharp and Dohme

Merck

Publisher

Wiley